Stroke Risk in Atrial Fibrillation Without Anticoagulation
Patients with persistent atrial fibrillation not receiving anticoagulation face a stroke risk that varies from approximately 0.5-1.8% per year depending on their CHA₂DS₂-VASc score, with risk escalating substantially as additional risk factors accumulate.
Risk Stratification Framework
The stroke risk for AF patients not on anticoagulation must be assessed using the CHA₂DS₂-VASc score 1, 2. This is the recommended tool across all contemporary guidelines and provides the most accurate risk stratification.
Annual Stroke Risk by CHA₂DS₂-VASc Score (Without Anticoagulation):
- Score 0 (men): 0% adjusted annual stroke risk 1
- Score 1 (men) or 2 (women with sex as only factor): 0.5-1.3% annual stroke risk 3, 4, 5
- Score 2 or higher: 2.2-4.0% annual stroke risk, increasing progressively 1
- Score ≥5: 1.8% or higher annual stroke risk 6
The most recent high-quality evidence from the SINGLE-AF trial (2026) demonstrated that patients with intermediate risk (CHA₂DS₂-VASc score of 1 in men, 2 in women) had a 1.5% cumulative incidence of stroke at 24 months without anticoagulation 5.
Age-Specific Considerations
For patients aged 66-74 years with AF but no other CHA₂DS₂-VASc risk factors, stroke risk increases progressively with age 7:
- Age 66: 0.7% annual stroke risk
- Age 74: 1.7% annual stroke risk
This represents more than a doubling of risk across this age range, even without additional comorbidities 7.
Real-World Outcomes Without Anticoagulation
Patients not receiving anticoagulation face substantially worse outcomes beyond just stroke risk 8:
- Death or dependency at 12 months: 33.5% (vs 19.8% with anticoagulation)
- Recurrent stroke: 27.2% (vs 9.9% with anticoagulation)
- 1.6-fold increased risk of death or dependency (HR 1.65)
- 2.5-fold increased risk of stroke (HR 2.46)
Critical Clinical Context
Approximately 24-64% of AF patients who should receive anticoagulation are not treated at the time of stroke presentation 9, 8, 10. The primary reasons include:
- History of major bleeding (18.7%)
- Physician-assessed high bleeding risk (17.1%)
- Patient refusal (17.6%)
- Frailty, dementia, or bedridden status 8
However, risk modeling consistently demonstrates that the benefits of anticoagulation in stroke and mortality reduction outweigh bleeding risks in patients with CHA₂DS₂-VASc ≥2 9.
Guideline-Based Risk Thresholds
The 2024 ESC Guidelines establish that a CHA₂DS₂-VASc score of 2 or more indicates elevated thromboembolic risk requiring oral anticoagulation 2. The 2012 ACCP guidelines recommend:
- CHADS₂ score 0: 1.9% annual stroke risk - no therapy suggested 11
- CHADS₂ score 1: 2.8% annual stroke risk - oral anticoagulation recommended over no therapy 11
- CHADS₂ score ≥2: 4.0-18.2% annual stroke risk - oral anticoagulation strongly recommended 11
Common Pitfalls
Do not use the temporal pattern of AF (paroxysmal vs persistent vs permanent) to determine stroke risk 2. Stroke risk is identical regardless of AF pattern when the same risk factors are present 1.
Female sex alone (without other risk factors) does not justify anticoagulation 3. European guidelines differentiate by requiring males to have ≥1 non-sex risk factor and females to have ≥2 points (meaning ≥1 non-sex risk factor) before considering anticoagulation 3.
Aspirin is not an acceptable alternative to anticoagulation for stroke prevention 2. The 2024 ESC guidelines explicitly state antiplatelet therapy is not recommended as an alternative to anticoagulation (Class III recommendation) 2.